Weir Matthew R
Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Kidney Int Suppl (2011). 2016 Apr;6(1):29-34. doi: 10.1016/j.kisu.2016.01.005. Epub 2016 Mar 14.
Hyperkalemia is associated with life-threatening cardiac arrhythmias and increased mortality. Hyperkalemia is most often observed in patients with chronic kidney disease and/or in those with congestive heart failure being treated with drugs that limit renal potassium excretion, especially drugs that inhibit the renin-angiotensin-aldosterone system. Treatment of hyperkalemia may be either acute, as needed during rapid changes in serum potassium, which are associated with cardiac arrhythmia, or chronic, which stabilizes serum potassium levels and limits the development of life-threatening arrhythmias. There are a number of both acute and chronic treatments available for the treatment of hyperkalemia, but some are limited by complex administration requirements and/or serious side effects. Hyperkalemia remains a vexing problem for clinicians, particularly in the care of patients with chronic kidney disease and cardiovascular disease.
高钾血症与危及生命的心律失常及死亡率增加相关。高钾血症最常出现在慢性肾脏病患者和/或接受限制肾脏排钾药物治疗的充血性心力衰竭患者中,尤其是那些抑制肾素 - 血管紧张素 - 醛固酮系统的药物。高钾血症的治疗可以是急性的,即在血清钾快速变化(与心律失常相关)时按需进行,也可以是慢性的,即稳定血清钾水平并限制危及生命的心律失常的发生。有多种急性和慢性治疗方法可用于治疗高钾血症,但有些方法受到复杂给药要求和/或严重副作用的限制。高钾血症仍然是临床医生面临的一个棘手问题,尤其是在慢性肾脏病和心血管疾病患者的护理中。